Information Provided By: 
Fly News Breaks for February 10, 2017
NBIX
Feb 10, 2017 | 08:16 EDT
Following Neurocrine's deal for U.S. commercial rights to opicapone for the treatment of Parkinson's disease, Oppenheimer analyst Jay Olson says he believes it has a clear strategic fit with Ingrezza and, if both are approved, would lead to a highly synergistic portfolio with promotional efforts targeting a shared physician audience. The analyst is encouraged by the timing and nature of this deal, which he believes demonstrates management confidence in Ingrezza. He reiterates an Outperform rating and $55 on Neurocrine's shares.
News For NBIX From the Last 2 Days
